![dragonfly-867888_1280](https://pharmaphorum.com/wp-content/uploads/2022/05/dragonfly-867888_1280.jpg)
Gilead dives deeper into NK cell therapies with Dragonfly de...
Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cance